• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Ypsomed to supply Bigfoot with insulin infusion sets for pivotal trial

October 24, 2017 By Sarah Faulkner

Ypsomed, Bigfoot

Ypsomed plans to supply Bigfoot Biomedical with a modified version of its Orbit infusion set for the pivotal trial of Bigfoot’s automated insulin delivery system, the companies said today.

Ypsomed’s Orbit infusion sets can be rotated 360°, giving users the freedom to move around, and are fitted using a heat-activated patch. The infusion sets are available with steel or soft cannulas, the company said, and Ypsomed plans to provide Bigfoot with an inserter for the company’s trial.

Bigfoot wrapped up the first clinical study of its automated insulin delivery system at the end of last year and hopes to start the pivotal trial next year.

“Both Ypsomed and Bigfoot Biomedical are dedicated to the development of products which simplify the everyday management of diabetes for those affected. Our partnership is an example of how consistently both companies follow this objective” Ypsomed CEO Simon Michel said in prepared remarks. “This cooperation gives us the opportunity of offering our popular Orbitinfusion sets to even more people with diabetes.”

“Ypsomed’s Orbit infusion set is thoughtfully designed,” Bigfoot president & CEO Jeffrey Brewer added. “We’re looking forward to incorporating a cannula and tubing that is flexible, reliable, and simple-to-operate into our clinical trial.”

In July, Bigfoot announced that it partnered with Abbott (NYSE:ABT) to bring together Abbott’s glucose monitoring tech and Bigfoot’s insulin delivery platform.

According to the deal, Abbott will provide Bigfoot with the next-gen version of its FreeStyle Libre continuous glucose monitor. The glucose monitor will be used to develop what the pair are touting as the first personalized system intended to optimize insulin delivery without the need for a fingerstick calibration.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Bigfoot Biomedical, Ypsomed

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS